<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.117462</article-id><article-id pub-id-type="publisher-id">ACM-44053</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210700000_49861473.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  肠道菌群与肝脏相关疾病的研究进展
  Research Progress of Intestinal Flora and Liver Related Diseases
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>惠</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>臻棋</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>学红</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>文霞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>丽萍</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青海大学研究生院，青海 西宁</addr-line></aff><aff id="aff3"><addr-line>青海大学附属医院消化内科，青海 西宁</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>07</month><year>2021</year></pub-date><volume>11</volume><issue>07</issue><fpage>3185</fpage><lpage>3190</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  肠道微生物群的组成与非酒精性脂肪肝病(Nonalcoholic fatty liver disease, NAFLD)、酒精性肝病(Alcoholic liver disease, ALD)、病毒性肝炎、自身免疫性肝病(autoimmune liver disease, AILD)、肝细胞癌(hepatocellular carcinoma, HCC)等多种慢性肝病的发病机制密切相关。本文旨在通过论述肠道菌群与肝脏相关疾病之间的相互关系，以期为肝脏相关疾病的临床研究提供更多理论依据，以期作为治疗肝脏相关疾病的新方向。
   The composition of intestinal microbiota is closely related to the pathogenesis of nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), viral hepatitis, autoimmune liver disease，AILD, hepatocellular carcinoma (HCC) and other chronic liver diseases. This paper aims to discuss the relationship between intestinal flora and liver related diseases, in order to provide more theoretical basis for clinical research of liver related diseases, and as a new direction for the treatment of liver related diseases.
 
</p></abstract><kwd-group><kwd>肠道菌群，非酒精性脂肪肝病，酒精性肝病，病毒性肝炎，自身免疫性肝病，肝细胞癌, Intestinal Flora</kwd><kwd> Nonalcoholic Fatty Liver Disease</kwd><kwd> Alcoholic Liver Disease</kwd><kwd> Viral Hepatitis</kwd><kwd>
Autoimmune Liver Disease</kwd><kwd> Hepatocellular Carcinoma</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>肠道微生物群的组成与非酒精性脂肪肝病(Nonalcoholic fatty liver disease, NAFLD)、酒精性肝病(Alcoholic liver disease, ALD)、病毒性肝炎、自身免疫性肝病(autoimmune liver disease, AILD)、肝细胞癌(hepatocellular carcinoma, HCC)等多种慢性肝病的发病机制密切相关。本文旨在通过论述肠道菌群与肝脏相关疾病之间的相互关系，以期为肝脏相关疾病的临床研究提供更多理论依据，以期作为治疗肝脏相关疾病的新方向。</p></sec><sec id="s2"><title>关键词</title><p>肠道菌群，非酒精性脂肪肝病，酒精性肝病，病毒性肝炎，自身免疫性肝病，肝细胞癌</p></sec><sec id="s3"><title>Research Progress of Intestinal Flora and Liver Related Diseases <sup> </sup></title><p>Hui Li<sup>1</sup>, Zhenqi Ma<sup>2*</sup>, Xuehong Wang<sup>2*</sup>, Wenxia Ma<sup>1</sup>, Liping Yang<sup>1</sup></p><p><sup>1</sup>Graduate School of Qinghai University, Xining Qinghai</p><p><sup>2</sup>Department of Gastroenterology, Qinghai University Affiliated Hospital, Xining Qinghai</p><p><img src="//html.hanspub.org/file/43-1572366x4_hanspub.png?20210723083100379" /></p><p>Received: Jun. 19<sup>th</sup>, 2021; accepted: Jul. 11<sup>th</sup>, 2021; published: Jul. 22<sup>nd</sup>, 2021</p><p><img src="//html.hanspub.org/file/43-1572366x5_hanspub.png?20210723083100379" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>The composition of intestinal microbiota is closely related to the pathogenesis of nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), viral hepatitis, autoimmune liver disease，AILD, hepatocellular carcinoma (HCC) and other chronic liver diseases. This paper aims to discuss the relationship between intestinal flora and liver related diseases, in order to provide more theoretical basis for clinical research of liver related diseases, and as a new direction for the treatment of liver related diseases.</p><p>Keywords:Intestinal Flora, Nonalcoholic Fatty Liver Disease, Alcoholic Liver Disease, Viral Hepatitis, Autoimmune Liver Disease, Hepatocellular Carcinoma</p><disp-formula id="hanspub.44053-formula32"><graphic xlink:href="//html.hanspub.org/file/43-1572366x7_hanspub.png?20210723083100379"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/43-1572366x8_hanspub.png?20210723083100379" /> <img src="//html.hanspub.org/file/43-1572366x9_hanspub.png?20210723083100379" /></p></sec><sec id="s5"><title>1. 肠道菌群概述</title><p>肠道微生物群(gutmicrobiota, GM)是一个由细菌、真菌和病毒组成的多样的生态系统，它们彼此之间以及与人体之间存在着特定的共生关系。目前，GM在人类健康的生理和病理中起着重要作用，参与消化、维生素B合成、免疫调节等功能。此外，GM还不可避免地对消化系统、呼吸系统、心血管系统等多种疾病的发病机制产生影响 [<xref ref-type="bibr" rid="hanspub.44053-ref1">1</xref>]。人体肠道细菌主要由拟杆菌门、厚壁菌门、放线菌门、变形菌门、疣微菌门等构成，以前两种为主(约占总体90%) [<xref ref-type="bibr" rid="hanspub.44053-ref2">2</xref>]，在很大程度上影响着整个菌群的功能，影响着宿主的生长发育、免疫调节功能和基本能量代谢，对机体各项生理、病理过程发挥重要调节作用 [<xref ref-type="bibr" rid="hanspub.44053-ref3">3</xref>]。肠–肝轴之间的相互作用是通过门静脉的血管通路直接将肠源性产物输送到肝脏，以及胆汁和抗体通过肝脏反馈到肠道的途径来建立的 [<xref ref-type="bibr" rid="hanspub.44053-ref4">4</xref>]。肠道屏障是由肠粘膜和血管内皮组成的功能性解剖结构，是肠道与肝脏连接的场所。肠道菌群通过肠–肝轴影响肝脏相关疾病的发生发展。</p></sec><sec id="s6"><title>2. 肠道菌群与ALD</title><p>酗酒是世界范围内肝损害的一个突出原因。除饮酒量和遗传易感性外，GM被认为是影响ALD肝损伤严重程度的关键因素。酒精使动物小肠和大肠过度生长并调节GM的组成。酒精及其降解产物破坏肠粘膜，导致肠道通透性增加和炎症浸润 [<xref ref-type="bibr" rid="hanspub.44053-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.44053-ref6">6</xref>]。摄入大量酒精后，肠源性PAMPs (如内毒素)增加 [<xref ref-type="bibr" rid="hanspub.44053-ref7">7</xref>]。乙醇消耗通过SCFAs调制改变GM的组成。除乙醇代谢物乙酸含量增加外，饮用酒精后肠内SCFAs含量较低 [<xref ref-type="bibr" rid="hanspub.44053-ref8">8</xref>]。Mutlu等人还研究了ALD的酗酒者和健康受试者的粘膜相关结肠微生物群。一个亚组患者表现出一种失调，类杆菌中位数较低，变形杆菌中位数较高。这项研究表明，酒精中毒可能存在肠-脑轴，这提供了某些证据表明肠道微生物群调节行为紊乱，如酒精依赖。因此，人们越来越认识到，肠道微生物群可能与酒精相关的人类疾病有关 [<xref ref-type="bibr" rid="hanspub.44053-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.44053-ref10">10</xref>]。慢性酒精滥用患者的血清脂多糖水平也会升高 [<xref ref-type="bibr" rid="hanspub.44053-ref11">11</xref>]。乙醇及其代谢物乙醛破坏紧密连接的能力是导致ALD患者高水平细菌易位的原因之一。此外，接受灌胃酒精喂养的小鼠出现肠道微生物区系紊乱，减少了长链脂肪酸的合成 [<xref ref-type="bibr" rid="hanspub.44053-ref12">12</xref>]。微生物群在严重酒精性肝炎(AH)中可能具有特殊的相关性，Llopis等人还指出，人类AH的疾病严重程度可以通过粪便微生物移植(FMT)转移到无菌(GF)和常规小鼠。研究发现，在对患有或不患有AH的患者进行FMT后，动物肝脏疾病的严重程度显著加重。相比之下，如果使用没有严重AH的人类供体进行FMT，则疾病表型为轻度 [<xref ref-type="bibr" rid="hanspub.44053-ref13">13</xref>]。</p></sec><sec id="s7"><title>3. 肠道菌群与NAFLD</title><p>NAFLD是全球最重要的肝病病因之一，全球发病率为25%。NAFLD是肝细胞癌的主要危险因素之一，预计将成为肝移植最常见的指标 [<xref ref-type="bibr" rid="hanspub.44053-ref14">14</xref>]。NAFLD是肝细胞内甘油三酯积聚的结果，被认为是肥胖和代谢综合征的肝表现。疾病谱包括非酒精性单纯性脂肪肝(NAFL)、非酒精性脂肪性肝炎(NASH)及其相关肝硬化和肝细胞癌 [<xref ref-type="bibr" rid="hanspub.44053-ref15">15</xref>]。NAFLD不仅可以导致肝病残疾和死亡，还与代谢综合征(metabolic syndrome, MetS)、2型糖尿病(type 2 diabetes mellitus, T2DM)、动脉硬化性心血管疾病以及结直肠肿瘤等的高发密切相关 [<xref ref-type="bibr" rid="hanspub.44053-ref16">16</xref>]。当前普遍认为NAFLD是一种与遗传–环境–代谢应激相关且无过量饮酒史、肝细胞脂肪变性和脂质贮积为特征的临床病理综合征 [<xref ref-type="bibr" rid="hanspub.44053-ref17">17</xref>]。迄今为止人们对NAFLD的发病机制还了解不多，目前广为认可的“多重打击学说” [<xref ref-type="bibr" rid="hanspub.44053-ref18">18</xref>] 的基础上，先天免疫调节紊乱、自噬、营养元素、肠–肝轴、表观遗传学也是影响NAFLD发展的重要因素。大量证据表明，肠道菌群失调在NAFLD及相关代谢紊乱中发挥重要作用。肝脏与胃肠道同为消化系统重要组成部分，不仅是人体重要的合成、解毒器官，也是参与人体免疫反应的器官 [<xref ref-type="bibr" rid="hanspub.44053-ref19">19</xref>]。由于肝脏与肠道特殊的解剖和生理关系，肠道微生物通过肝–肠循环，在肝脏损伤、慢性纤维化、炎症及肿瘤发生发展中发挥重要作用 [<xref ref-type="bibr" rid="hanspub.44053-ref20">20</xref>]。Le Roy等人证明了肠道微生物群在NAFLD发生中的作用。他们观察到，在高脂肪饮食治疗后，一定比例的小鼠出现肥胖、胰岛素抵抗和NAFLD。引人注目的是，在这组啮齿动物实验中，遗传背景和饮食环境完全相同；然而，由于不同的未知原因，微生物群对饮食的反应可能不同。尽管大多数被调查的小鼠确实出现了代谢紊乱(即，高血糖、全身炎症和脂肪变性)，但其他一些小鼠对饮食诱导的代谢紊乱有抵抗力，被认为是“无应答者”与“应答者”。有趣的是，“无应答者”的微生物群组成不同于“应答者”。通过使用无菌小鼠，他们证明了发生NAFLD的易感性是通过肠道微生物群移植传播的。因此，这组实验清楚地表明，特定的细菌种类与饮食诱因(如高脂喂养)引起的NAFLD发病有关 [<xref ref-type="bibr" rid="hanspub.44053-ref21">21</xref>]。</p></sec><sec id="s8"><title>4. 肠道菌群与病毒性肝病</title><p>病毒性肝病是一个主要的全球公共卫生问题，影响数亿人，并与显著的发病率和死亡率有关。甲型肝炎病毒(HAV)、乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)、丁型肝炎病毒(HDV)和戊型肝炎病毒(HEV)造成了全球的大部分负担。全球估计有2.57亿人携带乙肝病毒，7100万人携带丙型肝炎病毒。超过90%的负担是由于肝硬化和肝细胞癌(HCC)，这是慢性乙型肝炎(CHB)和慢性丙型肝炎(CHC)感染的后果 [<xref ref-type="bibr" rid="hanspub.44053-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.44053-ref23">23</xref>]。而影响病毒性肝炎发生、发展的因素，除了饮食、环境和遗传因素外，肠–肝轴也起着重要作用。既往研究已表明，慢性乙型肝炎和慢性丙型肝炎患者肝小叶坏死、肝细胞再生和储脂细胞分化等与内毒素有直接联系；肠道微生物群可能与慢性丙型肝炎的进展及相关并发症有关。最近，Aly等人比较了6例感染HCV的LC患者和8例健康人的肠道微生物群，提示慢性丙型肝炎患者可能存在微生物群重构 [<xref ref-type="bibr" rid="hanspub.44053-ref24">24</xref>]。此外，Heidrich等人采用横断面方法分析了95例CHC患者的肠道微生物群，包括38例肝硬化患者和50例健康对照者。他们表明，不仅肝脏疾病的阶段，而且HCV感染都与α多样性降低和不同的微生物群落模式有关 [<xref ref-type="bibr" rid="hanspub.44053-ref25">25</xref>]。我们的数据显示，与健康人相比，慢性丙型肝炎患者的肠道细菌多样性显著减少，并且这种减少与临床阶段的严重程度有关。随着共生细菌的减少，包括革兰科和瘤胃科细菌中，类杆菌(病毒链球菌和乳杆菌)主要在CH、LC和HCC患者中增加，肠杆菌科和类杆菌属在PNALT患者中短暂增加，差异有显著性 [<xref ref-type="bibr" rid="hanspub.44053-ref26">26</xref>]。</p></sec><sec id="s9"><title>5. 肠道菌群与AILD</title><p>AILD是一类病因尚不明、具有自身免疫基础的慢性肝病。AILD的特点为机体对自身肝脏组织失去耐受，肝脏出现病理性炎症损伤，血清可发现与疾病相关的自身抗体 [<xref ref-type="bibr" rid="hanspub.44053-ref27">27</xref>]。原发性胆管炎(PBC)和自身免疫性肝炎(AIH)是典型的自身免疫性肝病。自身免疫性肝病被认为是由遗传易感个体的环境因素引起的。基因组的广泛关联和小鼠模型的研究扩大了我们对自身免疫性肝病的认识，然而，疾病的发病机制仍不清楚。AIH表现为不明原因的慢性肝脏炎症。它通常影响青年到中年女性，并与自身抗体的存在和高蛋白血症有关 [<xref ref-type="bibr" rid="hanspub.44053-ref28">28</xref>]。然而，本病的发病机制尚不清楚。越来越多的人认识到肠道微生物的组成在影响对AIH的易感性方面起着至关重要的作用。Lin R等人报道了AIH患者肠道通透性增加和细菌移位，与疾病严重程度有关 [<xref ref-type="bibr" rid="hanspub.44053-ref29">29</xref>] [<xref ref-type="bibr" rid="hanspub.44053-ref30">30</xref>]。研究中，AIH中肠道微生物组成的变化主要表现为肠道微生物数量的增加。乳杆菌减少了这个属的丰度梭菌群 [<xref ref-type="bibr" rid="hanspub.44053-ref31">31</xref>]。PBC是一种进行性自身免疫性肝病，以门脉炎、免疫介导的肝内胆管破坏和血清中存在高度特异性的抗线粒体抗体为特征 [<xref ref-type="bibr" rid="hanspub.44053-ref32">32</xref>] [<xref ref-type="bibr" rid="hanspub.44053-ref33">33</xref>]。为了研究PBC患者肠道微生物组分的变化，比较了属级和正常人肠道微生物的相对丰度。在属层次上，PBC患者与健康人相比，12种细菌的相对丰度发生了变化。八种细菌(嗜血杆菌、维氏菌、梭菌、乳杆菌、链球菌、假单胞菌、克雷伯氏菌、肠杆菌科)增加了相对丰度，而四个(苏特氏菌、螺旋藻、肠杆菌、类杆菌)相对丰度下降 [<xref ref-type="bibr" rid="hanspub.44053-ref28">28</xref>]。综上，肠道菌群在自身免疫性肝病的发生发展中发挥重要作用，具体机制仍待进一步研究。</p></sec><sec id="s10"><title>6. 肠道菌群与HCC</title><p>HCC是全球第三大恶性肿瘤死亡原因。肝癌几乎完全发生在慢性肝病患者身上，这是由肝脏损伤、炎症和再生的恶性循环驱动的，通常持续数十年。越来越多的证据表明细菌微生物组在肝癌的发展中起着关键的作用 [<xref ref-type="bibr" rid="hanspub.44053-ref34">34</xref>]。越来越多的证据表明，HCC患者和健康对照组的微生物群存在很大差异，包括存在的物种、微生物群数量和产生的代谢物 [<xref ref-type="bibr" rid="hanspub.44053-ref35">35</xref>]。Ren [<xref ref-type="bibr" rid="hanspub.44053-ref36">36</xref>] 等收集了419份样本，并对其进行了16S rRNA MiSeq测序，发现早期HCC中粪便微生物多样性增加，如放线菌门、Gemmiger和Parabacteroides。与健康对照组相比，II期和III期原发性肝癌患者中的变形菌数量显著增加 [<xref ref-type="bibr" rid="hanspub.44053-ref37">37</xref>]，最近的研究表明HCC患者粪便中大肠杆菌含量明显高于健康人，提示大肠杆菌可能参与了肝癌的发生过程 [<xref ref-type="bibr" rid="hanspub.44053-ref38">38</xref>]。研究显示早期肝癌患者中，产丁酸杆菌科减少，而克雷伯氏菌和嗜血杆菌与对照组相比，脂多糖(LPS)的产生增加。丁酸盐作为肠道粘膜的主要能量来源，被认为是宿主细胞基因表达、炎症、分化和凋亡的重要调节因子，在细菌能量代谢和肠道健康中起着关键作用 [<xref ref-type="bibr" rid="hanspub.44053-ref39">39</xref>]。因此，产生丁酸的细菌的减少可能会促进肠粘膜的破坏，从而促进肝癌的发展。</p></sec><sec id="s11"><title>7. 结语与展望</title><p>肠道微生物群与肝脏有密切的关系，在慢性肝病发病中起着重要作用，但其在不同肝病中的作用机制尚不清楚。肝脏疾病的微生物组学研究是近年来发展起来的一个令人兴奋的新的研究领域，特别是临床前的实验研究表明，微生物因素是许多不同肝脏疾病不同阶段的驱动力。微生物群影响多种病理生理过程，如肝脏脂肪变性、肝脏炎症、纤维化发展和HCC。这些研究表明了微生物群在这些疾病中起着关键作用。然而，还需要更多的研究，尤其是宏基因组和代谢组学研究，以期提供肠道微生物及其代谢物在各种肝病机制中发挥的作用，以期作为治疗肝脏相关疾病治疗的新靶点。</p></sec><sec id="s12"><title>文章引用</title><p>李 惠,马臻棋,王学红,马文霞,杨丽萍. 肠道菌群与肝脏相关疾病的研究进展Research Progress of Intestinal Flora and Liver Related Diseases[J]. 临床医学进展, 2021, 11(07): 3185-3190. https://doi.org/10.12677/ACM.2021.117462</p></sec><sec id="s13"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44053-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Milosevic, I., Vujovic, A., Barac, A., Djelic, M., Korac, M., Radovanovic Spurnic, A., Gmizic, I., Stevanovic, O., Djordjevic, V., Lekic, N., Russo, E. and Amedei, A. (2019) Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature. International Journal of Molecular Sciences, 20, 395.  
&lt;br&gt;https://doi.org/10.3390/ijms20020395</mixed-citation></ref><ref id="hanspub.44053-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Lozupone, C.A., Stombaugh, J.I., Gordon, J.I., Jansson, J.K. and Knight, R. (2012) Diversity, Stability and Resilience of the Human Gut Microbiota. Nature, 489, 220-230. &lt;br&gt;https://doi.org/10.1038/nature11550</mixed-citation></ref><ref id="hanspub.44053-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Tremaroli, V. and Bäckhed, F. (2012) Functional Interactions between the Gut Microbiota and Host Metabolism. Nature, 489, 242-249. &lt;br&gt;https://doi.org/10.1038/nature11552</mixed-citation></ref><ref id="hanspub.44053-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Albillos, A., de Gottardi, A. and Rescigno, M. (2020) The Gut-Liver Axis in Liver Disease: Pathophysiological Basis for Therapy. Journal of Hepatology, 72, 558-577. &lt;br&gt;https://doi.org/10.1016/j.jhep.2019.10.003</mixed-citation></ref><ref id="hanspub.44053-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Cassard, A.M. and Ciocan, D. (2017) Microbiota, a Key Player in Alcoholic Liver Disease. Clinical and Molecular Hepatology, 24, 100-107. &lt;br&gt;https://doi.org/10.3350/cmh.2017.0067</mixed-citation></ref><ref id="hanspub.44053-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Hartmann, P., Seebauer, C.T. and Schnabl, B. (2015) Alcoholic Liver Disease: The Gut Microbiome and Liver Cross Talk. Alcoholism: Clinical and Experimental Research, 39, 763-775. &lt;br&gt;https://doi.org/10.1111/acer.12704</mixed-citation></ref><ref id="hanspub.44053-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Szabo, G. (2014) Gut-Liver Axis in Alcoholic Liver Disease. Gastroenterology, 148, 30-36.  
&lt;br&gt;https://doi.org/10.1053/j.gastro.2014.10.042</mixed-citation></ref><ref id="hanspub.44053-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Xie, G., Zhong, W., Zheng, X., Li, Q., Qiu, Y., Li, H., Chen, H., Zhou, Z. and Jia, W. (2013) Chronic Ethanol Consumption Alters Mammalian Gastrointestinal Content Metabolites. Journal of Proteome Research, 12, 3297-3306.  
&lt;br&gt;https://doi.org/10.1021/pr400362z</mixed-citation></ref><ref id="hanspub.44053-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Macnaughtan, J. and Jalan, R. (2015) Clinical and Pathophysiological Consequences of Alterations in the Microbiome in Cirrhosis. The American Journal of Gastroenterology, 110, 1399-1410. &lt;br&gt;https://doi.org/10.1021/pr400362z</mixed-citation></ref><ref id="hanspub.44053-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Leclercq, S., Matamoros, S., Cani, P.D., et al. (2014) Intestinal Permeability, Gut-Bacterial Dysbiosis, and Behavioral Markers of Alcohol-Dependence Severity. Proceedings of the National Academy of Sciences of the United States of America, 111, E4485-E4493. &lt;br&gt;https://doi.org/10.1073/pnas.1415174111</mixed-citation></ref><ref id="hanspub.44053-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Pradere, J.P., Troeger, J.S., Dapito, D.H., Mencin, A.A. and Schwabe, R.F. (2010) Toll-Like Receptor 4 and Hepatic Fibrogenesis. Seminars in Liver Disease, 30, 232-244. &lt;br&gt;https://doi.org/10.1055/s-0030-1255353</mixed-citation></ref><ref id="hanspub.44053-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Chen, P., et al. (2015) Supplementation of Saturated Long-Chain Fatty Acids Maintains Intestinal Eubiosis and Reduces Ethanol-Induced Liver Injury in Mice. Gastroenterology, 148, 203-214.e216.  
&lt;br&gt;https://doi.org/10.1053/j.gastro.2014.09.014</mixed-citation></ref><ref id="hanspub.44053-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Llopis, M., Cassard, A.M., Wrzosek, L., et al. (2016) Intestinal Microbiota Contributes to Individual Susceptibility to Alcoholic Liver Disease. Gut, 65, 830-839. &lt;br&gt;https://doi.org/10.1136/gutjnl-2015-310585</mixed-citation></ref><ref id="hanspub.44053-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Younossi, Z.M., Marchesini, G., Pinto-Cortez, H. and Petta, S. (2018) Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. Transplantation, 2018, Article ID: 30335697. &lt;br&gt;https://doi.org/10.1002/lt.25003</mixed-citation></ref><ref id="hanspub.44053-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版) [J]. 胃肠病学和肝病学杂志, 2010, 19(6): 483-487.</mixed-citation></ref><ref id="hanspub.44053-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">非酒精性脂肪性肝病防治指南(2018更新版) [J]. 传染病信息, 2018, 31(5): 393-402+420.</mixed-citation></ref><ref id="hanspub.44053-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Michelotti, G.A., Machado, M.V. and Diehl, A.M. (2013) NAFLD, NASH and Liver Cancer. Nature Reviews Gastroenterology Hepatology, 10, 656-665. &lt;br&gt;https://doi.org/10.1038/nrgastro.2013.183</mixed-citation></ref><ref id="hanspub.44053-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Buzzetti, E., Pinzani, M. and Tsochatzis, E.A. (2016) The Multiple-Hit Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD). Metabolism, 65, 1038-1048. &lt;br&gt;https://doi.org/10.1016/j.metabol.2015.12.012</mixed-citation></ref><ref id="hanspub.44053-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">柳惠未, 叶桦. 肠道菌群在非酒精性脂肪性肝病发病机制中的作用[J]. 中国现代医生, 2019, 57(6): 163-168.</mixed-citation></ref><ref id="hanspub.44053-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">廉晓晓, 郭晓霞. 肠-肝轴学说的研究进展[J]. 中西医结合肝病杂志, 2017, 27(4): 251-254.</mixed-citation></ref><ref id="hanspub.44053-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Le Roy, T., Llopis, M., Lepage, P., et al. (2013) Intestinal Microbiota Determines Development of Non-Alcoholic Fatty Liver Disease in Mice. Gut, 62, 1787-1794. &lt;br&gt;https://doi.org/10.1136/gutjnl-2012-303816</mixed-citation></ref><ref id="hanspub.44053-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2017) Global Hepatitis Report 2017. Geneva.  
&lt;br&gt;https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en</mixed-citation></ref><ref id="hanspub.44053-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2016) Global Health Sector Strategy on Viral Hepatitis, 2016-2021. Geneva.  
http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf?ua51</mixed-citation></ref><ref id="hanspub.44053-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Aly, A.M., Adel, A., El-Gendy, A.O., Essam, T.M. and Aziz, R.K. (2016) Gut Microbiome Alterations in Patients with Stage 4 Hepatitis C. Gut Pathogens, 8, 42. &lt;br&gt;https://doi.org/10.1186/s13099-016-0124-2</mixed-citation></ref><ref id="hanspub.44053-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Heidrich, B., Vital, M., Plumeier, I., et al. (2018) Intestinal Microbiota in Patients with Chronic Hepatitis C with and without Cirrhosis Compared with Healthy Controls. Liver International, 38, 50-58. &lt;br&gt;https://doi.org/10.1111/liv.13485</mixed-citation></ref><ref id="hanspub.44053-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Inoue, T., Nakayama, J., Moriya, K., Kawaratani, H., Momoda, R., Ito, K., Iio, E., Nojiri, S., Fujiwara, K., Yoneda, M., Yoshiji, H. and Tanaka, Y. (2018) Gut Dysbiosis Associated with Hepatitis C Virus Infection. Clinical Infectious Diseases, 67, 869-877. &lt;br&gt;https://doi.org/10.1093/cid/ciy205</mixed-citation></ref><ref id="hanspub.44053-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">王睿, 王绮夏, 马雄. 肠道微生态与自身免疫性肝病[J]. 实用肝脏病杂志, 2020, 23(6): 773-776.</mixed-citation></ref><ref id="hanspub.44053-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Abe, K., Fujita, M., Hayashi, M., Okai, K., Takahashi, A. and Ohira, H. (2020) Gut and Oral Microbiota in Autoimmune Liver Disease. Fukushima Journal of Medical Science, 65, 71-75. &lt;br&gt;https://doi.org/10.5387/fms.2019-21</mixed-citation></ref><ref id="hanspub.44053-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Lin, R., Zhou, L., Zhang, J. and Wang, B. (2015) Abnormal Intestinal Permeability and Microbiota in Patients with Autoimmune Hepatitis. International Journal of Clinical and Experimental Pathology, 8, 5153-5160.</mixed-citation></ref><ref id="hanspub.44053-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Wei, Y., Li, Y., Yan, L., Sun, C., Miao, Q., Wang, Q., Xiao, X., Lian, M., Li, B., Chen, Y., Zhang, J., Li, Y., Huang, B., Li, Y., Cao, Q., Fan, Z., Chen, X., Fang, J.Y., Gershwin, M.E., Tang, R. and Ma, X. (2019) Alterations of Gut Microbiome in Autoimmune Hepatitis. Gut, 69, 569-577. &lt;br&gt;https://doi.org/10.1136/gutjnl-2018-317836</mixed-citation></ref><ref id="hanspub.44053-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Abe, K., Takahashi, A., Fujita, M., Imaizumi, H., Hayashi, M., Okai, K., et al. (2018) Dysbiosis of Oral Microbiota and Its Association with Salivary Immunological Biomarkers in Autoimmune Liver Disease. PLoS ONE, 13, e0198757.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0198757</mixed-citation></ref><ref id="hanspub.44053-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Kaplan, M.M. and Gershwin, M.E. (2005) Primary Biliary Cirrhosis. The New England Journal of Medicine, 353, 1261-1273. &lt;br&gt;https://doi.org/10.1056/NEJMra043898</mixed-citation></ref><ref id="hanspub.44053-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Selmi, C., Bowlus, C.L., Gershwin, M.E. and Coppel, R.L. (2011) Primary Biliary Cirrhosis. The Lancet, 377, 1600-1609.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(10)61965-4</mixed-citation></ref><ref id="hanspub.44053-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Yu, L.X. and Schwabe, R.F. (2017) The Gut Microbiome and Liver Cancer: Mechanisms and Clinical Translation. Nature Reviews Gastroenterology &amp; Hepatology, 14, 527-539. &lt;br&gt;https://doi.org/10.1038/nrgastro.2017.72</mixed-citation></ref><ref id="hanspub.44053-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Gupta, H., Youn, G.S., Shin, M.J. and Suk, K.T. (2019) Role of Gut Microbiota in Hepatocarcinogenesis. Microorganisms, 7, 121. &lt;br&gt;https://doi.org/10.20944/preprints201903.0267.v1</mixed-citation></ref><ref id="hanspub.44053-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Ren, Z., Li, A., Jiang, J., Zhou, L., Yu, Z., Lu, H., Xie, H., Chen, X., Shao, L., Zhang, R., Xu, S., Zhang, H., Cui, G., Chen, X., Sun, R., Wen, H., Lerut, J.P., Kan, Q., Li, L. and Zheng, S. (2019) Gut Microbiome Analysis as a Tool towards Targeted Non-Invasive Biomarkers for Early Hepatocellular Carcinoma. Gut, 68, 1014-1023.  
&lt;br&gt;https://doi.org/10.1136/gutjnl-2017-315084</mixed-citation></ref><ref id="hanspub.44053-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Wan, M.L.Y. and El-Nezami, H. (2018) Targeting Gut Microbiota in Hepatocellular Carcinoma: Probiotics as a Novel Therapy. Hepatobiliary Surgery, 7, 11-20. &lt;br&gt;https://doi.org/10.21037/hbsn.2017.12.07</mixed-citation></ref><ref id="hanspub.44053-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Grat, M., Wronka, K.M., Krasnodebski, M., Masior, L., Lewandowski, Z., Kosinska, I., Grat, K., Stypulkowski, J., Rejowski, S., Wasilewicz, M., Galecka, M., Szachta, P. and Krawczyk, M. (2016) Profile of Gut Microbiota Associated with the Presence of Hepatocellular Cancer in Patients with Liver Cirrhosis. Transplantation Proceedings, 48, 1687-1691. &lt;br&gt;https://doi.org/10.1016/j.transproceed.2016.01.077</mixed-citation></ref><ref id="hanspub.44053-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Louis, P. and Flint, H.J. (2009) Diversity, Metabolism and Microbial Ecology of Butyrate-Producing Bacteria from the Human Large Intestine. FEMS Microbiology Letters, 294, 1-8. &lt;br&gt;https://doi.org/10.1111/j.1574-6968.2009.01514.x</mixed-citation></ref></ref-list></back></article>